As HER-3 is expressed by all HNSCC cell lines used in this study and the HER-3 expression is known to be linked to HNSCC mortality, this protein seems to be a suitable tumor antigen for developing cancer immunotherapy9, 10. The gene discussed is ERBB3; the disease is neoplasm.